This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO) and Haleon PLC Sponsored ADR (HLN)

Tipranks - Tipranks - Tue May 26, 2:36AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bio-Rad Laboratories (BIO) and Haleon PLC Sponsored ADR (HLN).

Memorial Day Sale – Claim 70% Off TipRanks

Bio-Rad Laboratories (BIO)

Wells Fargo analyst Brandon Couillard maintained a Hold rating on Bio-Rad Laboratories on May 22 and set a price target of $310.00. The company’s shares closed last Friday at $287.74.

According to TipRanks.com, Couillard is a 5-star analyst with an average return of 15.6% and a 59.1% success rate. Couillard covers the Healthcare sector, focusing on stocks such as BillionToOne, Inc. Class A, Guardant Health, and GeneDx Holdings. ;'>

Bio-Rad Laboratories has an analyst consensus of Hold, with a price target consensus of $301.25, a 4.8% upside from current levels. In a report issued on May 21, Jefferies also maintained a Hold rating on the stock with a $275.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Haleon PLC Sponsored ADR (HLN)

In a report issued on May 20, Taylor Conrad from Argus Research maintained a Buy rating on Haleon PLC Sponsored ADR, with a price target of $11.00. The company’s shares closed last Friday at $9.29.

According to TipRanks.com, Conrad is a 4-star analyst with an average return of 7.2% and a 59.2% success rate. Conrad covers the Consumer Goods sector, focusing on stocks such as Coca-Cola Europacific Partners, Kimberly Clark, and Philip Morris. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Haleon PLC Sponsored ADR with a $13.92 average price target, implying a 49.4% upside from current levels. In a report issued on May 5, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $10.50 price target.

Read More on BIO:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).